 |
|
Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients
September 15, 2005Results from two Phase II studies to be announced on Wednesday 14th September support efficacy profile of sitagliptin, a novel DPP-IV inhibitor
There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. [3] As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycaemia for patients with type 2 diabetes. The results of the two Phase II studies indicate that sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.
In the Phase II studies of more than 1,000 patients, 'sitagliptin'', Merck Sharp & Dohme's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycaemic control in patients with type 2 diabetes and exhibited a safety and tolerability profile similar to placebo. In addition, patients taking sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia.
"Results from the studies conducted to date are very promising," said Peter Stein, Senior Director in Clinical Research, Metabolism, Merck Research Laboratories, Rahway, NJ, USA. "The need for well tolerated therapies which achieve better glycaemic control than current therapies is well known and we are confident that these short-term clinical studies demonstrate proof of concept for sitagliptin, offering a new hope for type 2 diabetes patients. Ongoing Phase III trials should provide greater insight into the efficacy and tolerability profile of sitagliptin over a longer period of time".
Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly reduced HbA1c (A1C) from baseline as compared to placebo with an average reduction of 0.6 percent observed in the sitagliptin 100 mg once daily group (p<.001).
The majority of the patients in this study had mild to moderate hyperglycaemia. The mean baseline A1C was approximately 7.7 with 28.8 percent of patients having a baseline A1C at or less than 7.0 percent. Observed differences in A1C between patients taking sitagliptin and patients administered placebo were greatest in those patients with a higher baseline A1C at randomization. In patients with a higher A1C baseline (i.e., between 8.5 and 10 percent), a 0.8 percent reduction, relative to placebo, was seen in patients randomized to the 100 mg once daily dose of sitagliptin using data carried forward, that is including patients whether they completed the study or not. A mean 1.1 percent reduction in A1C relative to placebo was observed in patients taking sitagliptin using data from patients who completed the study as per study protocol.
In this study, 552 type 2 diabetes patients, aged 30-74 years and with an HbA1C of 5.8 - 10.4% were randomized to one of five treatment groups: Placebo; sitagliptin (25 mg, 50 mg, or 100 mg) oral tablets once daily; or sitagliptin 50 mg oral tablets twice daily. Treatment with sitagliptin was generally well tolerated and resulted in no significant weight gain or incidence of GI related adverse events. Only one adverse event of hypoglycaemia was reported in each of the four sitagliptin treatment groups, compared to no adverse events of hypoglycaemia reported in the placebo group.
Study 2: Efficacy and tolerability of sitagliptin
The second study presented was a randomized, double-blind, placebo-controlled study, which evaluated the efficacy and tolerability of sitagliptin in 743 patients with type 2 diabetes. The majority of the patients in this study had mild to moderate hyperglycaemia (mean baseline A1C of 7.8-7.9 percent). Patients were randomized to one of six treatment groups: placebo; sitagliptin (5mg, 12.5 mg, 25 mg, or 50 mg oral tablets twice daily); or the sulfonylurea, glipizide, 5 mg titrated to 20 mg. After a 12 week treatment period, sitagliptin significantly reduced A1C from baseline compared to placebo. The largest reduction in the patients treated with sitagliptin was 0.77 percent p<0.001, in the 50 mg twice-daily treatment group. Patients taking glipizide showed a 1.0 percent reduction from baseline in A1C. In the active treatment groups, placebo subtracted A1C results did not appear to reach a plateau.
Treatment with sitagliptin was generally well tolerated and resulted in no significant weight gain. Patients treated with glipizide had an average weight gain of 1.1 kilogram relative to placebo. Adverse event reports of hypoglycaemia were observed in 4 percent of patients taking sitagliptin, 17 percent of patients taking glipizide and 2 percent of patients taking placebo.
"The loss of efficacy with sulfonylureas is well described. Longer term studies with an appropriate once daily dose of sitagliptin will address the full efficacy and potential durability of sitagliptin versus glipizide," commented Russell Scott MD, PhD, Professor of Medicine, Director of Diabetes and Lipid Research Group, Christchurch Hospital and School of Medicine, New Zealand.
###
About sitagliptin
Sitagliptin is an investigational medicine now under development by Merck & Co. for the treatment of type 2 diabetes. If approved, sitagliptin would be a member of a new class of antihyperglycaemic agents called DPP-IV inhibitors, which inhibit the DPP-4 enzyme that normally inactivates the incretin gut hormones GLP-1 and GIP. Sitagliptin is expected to lower blood glucose levels by increasing the level of active incretin hormones which increase insulin from pancreatic beta-cells and decrease glucagon from pancreatic alpha cells in a glucose-dependent manner (when blood glucose is elevated and not when blood glucose is low).
About Merck
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
Forwarding-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.
Merck & Co., Inc.
Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly reduced HbA1c (A1C) from baseline as compared to placebo with an average reduction of 0.6 percent observed in the sitagliptin 100 mg once daily group (p<.001).
The majority of the patients in this study had mild to moderate hyperglycaemia. The mean baseline A1C was approximately 7.7 with 28.8 percent of patients having a baseline A1C at or less than 7.0 percent. Observed differences in A1C between patients taking sitagliptin and patients administered placebo were greatest in those patients with a higher baseline A1C at randomization. In patients with a higher A1C baseline (i.e., between 8.5 and 10 percent), a 0.8 percent reduction, relative to placebo, was seen in patients randomized to the 100 mg once daily dose of sitagliptin using data carried forward, that is including patients whether they completed the study or not. A mean 1.1 percent reduction in A1C relative to placebo was observed in patients taking sitagliptin using data from patients who completed the study as per study protocol.
In this study, 552 type 2 diabetes patients, aged 30-74 years and with an HbA1C of 5.8 - 10.4% were randomized to one of five treatment groups: Placebo; sitagliptin (25 mg, 50 mg, or 100 mg) oral tablets once daily; or sitagliptin 50 mg oral tablets twice daily. Treatment with sitagliptin was generally well tolerated and resulted in no significant weight gain or incidence of GI related adverse events. Only one adverse event of hypoglycaemia was reported in each of the four sitagliptin treatment groups, compared to no adverse events of hypoglycaemia reported in the placebo group.
Study 2: Efficacy and tolerability of sitagliptin
The second study presented was a randomized, double-blind, placebo-controlled study, which evaluated the efficacy and tolerability of sitagliptin in 743 patients with type 2 diabetes. The majority of the patients in this study had mild to moderate hyperglycaemia (mean baseline A1C of 7.8-7.9 percent). Patients were randomized to one of six treatment groups: placebo; sitagliptin (5mg, 12.5 mg, 25 mg, or 50 mg oral tablets twice daily); or the sulfonylurea, glipizide, 5 mg titrated to 20 mg. After a 12 week treatment period, sitagliptin significantly reduced A1C from baseline compared to placebo. The largest reduction in the patients treated with sitagliptin was 0.77 percent p<0.001, in the 50 mg twice-daily treatment group. Patients taking glipizide showed a 1.0 percent reduction from baseline in A1C. In the active treatment groups, placebo subtracted A1C results did not appear to reach a plateau.
Treatment with sitagliptin was generally well tolerated and resulted in no significant weight gain. Patients treated with glipizide had an average weight gain of 1.1 kilogram relative to placebo. Adverse event reports of hypoglycaemia were observed in 4 percent of patients taking sitagliptin, 17 percent of patients taking glipizide and 2 percent of patients taking placebo.
"The loss of efficacy with sulfonylureas is well described. Longer term studies with an appropriate once daily dose of sitagliptin will address the full efficacy and potential durability of sitagliptin versus glipizide," commented Russell Scott MD, PhD, Professor of Medicine, Director of Diabetes and Lipid Research Group, Christchurch Hospital and School of Medicine, New Zealand.
###
About sitagliptin
Sitagliptin is an investigational medicine now under development by Merck & Co. for the treatment of type 2 diabetes. If approved, sitagliptin would be a member of a new class of antihyperglycaemic agents called DPP-IV inhibitors, which inhibit the DPP-4 enzyme that normally inactivates the incretin gut hormones GLP-1 and GIP. Sitagliptin is expected to lower blood glucose levels by increasing the level of active incretin hormones which increase insulin from pancreatic beta-cells and decrease glucagon from pancreatic alpha cells in a glucose-dependent manner (when blood glucose is elevated and not when blood glucose is low).
About Merck
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
Forwarding-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.
Merck & Co., Inc.
Diabetes Current Events and Diabetes News RSSFlaxseed oil and osteoporosis
Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health.
Diabetes surgery summit consensus lays foundation for new field of medicine
A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery.
ESC to give talks on Diabetes in three cities in China
As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou.
New research shows versatility of amniotic fluid stem cells
For the first time, scientists have demonstrated that stem cells found in amniotic fluid meet an important test of potential to become specialized cell types, which suggests they may be useful for treating a wider array of diseases and conditions than scientists originally thought.
First reconstitution of an epidermis from human embryonic stem cells
Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM* Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells.
An atomic-level look at an HIV accomplice
Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity.
Scripps research scientists find new link between insulin and core body temperature
A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature.
Scientists find molecular trigger that helps prevent aging and disease
Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease?
Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
Night Beat, Overtime and a Disrupted Sleep Pattern Can Harm Officers' Health
A police officer who works the night shift, typically from 8 p.m. to 4 a.m., already is at a disadvantage when it comes to getting a good "night's" sleep.
More Diabetes Current Events and Diabetes News Articles
 |
The First Year: Type 2 Diabetes: An Essential Guide for the Newly Diagnosed (First Year, The) by Gretchen Becker (Author), Allison B. Goldfine (Foreword) After Gretchen Becker was diagnosed with type 2 diabetes in 1996, she educated herself on every aspect of this chronic condition — by reading medical and scientific books and journals, talking with doctors and listening to her own body. In 2001, she marshaled everything she had learned as a "patient-expert" into the first edition of this book, which she has now completely updated and revised. The First Year®—Type 2 Diabetes uniquely guides you step-by-step through your first year with diabetes, walking you through everything you need to learn and do each day of your first week after diagnosis, each subsequent week of the first month, and each subsequent month of the crucial first year. In clear, concise, accessible language, Becker covers a wide range of practical, medical, and... |
 |
Diabetes For Dummies (For Dummies (Health & Fitness)) by Alan L. Rubin MD (Author) Covers the latest glucose meters and insulin treatments The straight facts on treating diabetes successfully and living a full life Want to know how to manage diabetes? Leading diabetes expert Dr. Alan Rubin gives you reassuring, authoritative guidance in putting together a state-of-the-art treatment program. You'll learn about all the advances in monitoring glucose, the latest medications, and how to develop a diet and exercise plan to stay healthy. You'll also see how to overcome insurance and on-the-job obstacles. Discover how to: Reduce your diabetes risk Understand the different types of diabetes Manage diabetes in children and the elderly Prevent long-term complications Get the support you need |
 |
Diabetes Health Pack-Nature Made Multivitamin & Mineral Supplement, 60 Packets by Nature Made Nature Made® Diabetes Health Pack provides essential nutrients that may be lacking due to the strain diabetes can often put on the bodys health. Each pack provides a complete, full potency formulation of vitamins, minerals and alpha lipoic acid. |
 |
The Official Pocket Guide to Diabetic Exchanges by American Diabetes Association (Author) Every day, every meal, millions and millions of people count on the world-famous Exchange Lists for Meal Planning to make sure they're choosing the right kinds of foods and portion sizes from the various food groups. Now people with diabetes can take the Exchange Lists with them to the grocery store or to restaurants with the Official Pocket Guide to Diabetic Exchanges. Measuring just 3.5" x 6", this little powerhouse is jam-packed with the exact same information found in the standard exchange lists, yet it fits conveniently into a purse or coat pocket. |
 |
Blood Sugar 101: What They Don't Tell You About Diabetes by Jenny Ruhl (Author) Based on the award winning Bloodsugar101.com web site, this book explains what peer-reviewed research published in top medical journals has to say about: What is a normal blood sugar? How does diabetes develop? What really causes diabetes? What blood sugar levels cause complications? Must you deteriorate? What diet is right for you? How can you make that diet work? What medications are safe? What supplements lower blood sugar? Written in clear and understandable language, this book provides all the tools needed to understand how blood sugar works and achieve blood sugar health. |
 |
Betty Crocker's Diabetes Cookbook: Everyday Meals, Easy as 1-2-3 by Betty Crocker Editors (Author) At last! This special cookbook puts flavor and choice back on the menu for people with diabetes and their families Betty Crocker, America's most trusted friend in the kitchen, has teamed up with the International Diabetes Center (IDC)--one of the leading medical centers--to create an indispensable source of easy-to-make recipes and up-to-the-minute food and nutrition information for the growing numbers of people who have diabetes, more than 15 million of them. Here is the first cookbook to include recipes featuring Carbohydrate Choices--the new, simplified approach to meal planning recommended by the American Diabetes Association. For people who find diet exchanges too hard, too limiting or too much work, this new method is a real breakthrough. Each of the book's 140 recipes... |
 |
Medport Diabetes Travel Organizer From GMS Holds Two Weeks Supplies/ Will Hold Syringes,vials Pens Secure(well Constructed ,One of the Nicest Diabetic Travel Bags on the Market) a Great Value - Cools for up to 18 Hrs Comes with 2-6 Oz Polar Tech Gel Paks by Medport Holds enough supplies for up to two weeks. Cool side carries insulin and MED IceTM. Room temperature side carries meter and supplies. Detachable medical waste pouch provides a safe alternative to store medical waste until properly disposed. Convenient handy carry strap. Includes two MED IceTM refreezable ice packs. Measures 9 in. x 6 in. x . This item only available in black. |
 |
Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars by Richard K. Bernstein (Author) The standard text on living with diabetes, newly revised and updated with all the latest scientific findings. Since its first publication in 1997, DR. BERNSTEIN'S DIABETES SOLUTION has become the treatment of choice in the medical field. In this revised and updated edition of his work, Dr. Bernstein provides an accessible, detailed guide to his revolutionary approach to normalizing blood sugars and thereby preventing or reversing long-term complications of diabetes. He offers the most up-to-date information on new products, medications, and supplements, and outlines a plan to reverse the obesity that underlies most cases of Type II diabetes. Dr. Bernstein discusses breakthrough science and potential cures, and has added information on the new insulins and insulin ... |
 |
The 4-Ingredient Diabetes Cookbook: Simple, Quick, and Delicious Recipes Using Just 4 Ingredients or Less by Nancy Hughes (Author) |
 |
Tell Me What to Eat If I Have Diabetes: Nutrition You Can Live With by Elaine Magee (Author) Just because you have diabetes doesn't mean you can't enjoy life, eat well, and live healthy! Tell Me What to Eat If I Have Diabetes begins with a detailed, but non-technical overview of diabetes, specifically Type II diabetes. Elaine clearly presents the latest medical findings on what causes diabetes, available treatments, and the dietary implications of this disease. This revised edition of Tell Me What to Eat If I Have Diabetes includes: * How to use an individualized carbohydrate budget. * Practical tips to lower dangerous blood lipids. * Quick guide to understanding and using the glycemic index and glycemic load. * Revolutionary fiber tips (because you can't talk about carbohydrates, Type II diabetes, and great health without factoring in... |
| © 2009 BrightSurf.com |